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1. Introduction {#sec1}
===============

Despite a number of HIV prevention interventions and the scale-up of antiretroviral therapy (ART), HIV incidence remains unabated, with nearly two million new adult cases per year ([@bib48]). Stagnant incidence rates may be in part due to the failure to detect and treat acute HIV infection (AHI) ([@bib13]; [@bib40]). Data from clinical trials, phylogenetic research, and mathematical models support the importance of AHI in propagating the epidemic---the likelihood of transmission during AHI is higher due to the presence of very high viral load (up to 10-fold higher than set-point) and high infectivity of founder viruses ([@bib10]; [@bib19]; [@bib29]; [@bib36]). Furthermore, because AHI occurs soon after acquisition, this period of high infectivity often occurs before an individual knows s/he is infected ([@bib5]; [@bib17]; [@bib37]; [@bib45]). ([@bib23]) Phylogenetic studies have demonstrated the importance of AHI in driving HIV epidemics, estimating that individuals with AHI are a source of infection for 10--50% of all transmissions ([@bib5], [@bib7]; [@bib8]; [@bib11]; [@bib18]; [@bib20]; [@bib24]; [@bib27]; [@bib34]). It is increasingly clear that efforts to identify and treat individuals with acute or early HIV infection will be critical to bring about HIV epidemic control.

A public health approach to detection of and treatment during AHI is necessary, especially in concentrated HIV epidemics such as in Peru, where the HIV epidemic is concentrated in men who have sex with men (MSM) and transgender women (TW) ([@bib40]). Although HIV prevalence in the general population is estimated to be below 0.2% ([@bib47]), HIV prevalence has been reported to be up to 22% and 30% among MSM and TW, respectively ([@bib9]; [@bib41]; [@bib43]; [@bib46]). It is estimated that AHI accounts for 22--29% of onward HIV transmission in Peru ([@bib21]).

We conducted the *Sabes* study ("¿Sabes?" in Spanish means "Do you know?"): enrollment occurred between July 2013 and September 2015; follow-up was completed in 2017. A treatment-as-prevention (TasP) intervention, *Sabes* tested the hypothesis that intervening early (within 3 months of HIV acquisition) when viral load is high, would markedly reduce onward HIV transmission among high-risk populations of MSM and TW in Lima, Peru ([@bib28]). Newly HIV-infected (HIV+) MSM and TW in Lima were identified by frequent testing and rapidly linked to care by peer health navigators -- a modification of the role of peer health educators long used in Peru to increase HIV testing. Overall, 3,337 subjects were screened for HIV; 2,685 (80.5%) were negative and 2,109 began monthly testing for HIV infection using both serologic assays and HIV RNA testing. This intervention proved that frequent HIV testing and rapid linkage to care are feasible in high-risk populations. We identified 311 individuals shortly after HIV acquisition, 256 of whom were diagnosed within 3 months of HIV acquisition. The time since HIV acquisition for the remaining 54 participants could not be demonstrated to be 3 months or less ([@bib28]). Ninety percent of eligible participants were linked to the study clinic within 6 days.

The Sabes study showed the feasibility of a treatment-as-prevention strategy employing frequent HIV testing and rapid linkage to care among MSM and TW in Lima. However, it could not measure the impact of this intervention on HIV incidence over time. Mathematical modeling provides a useful framework for projecting potential population-level benefits of HIV prevention programs ([@bib33]; [@bib14], [@bib15]; [@bib16]; [@bib42]; [@bib50]; [@bib49]; [@bib54]). In this paper we evaluate the effectiveness of detecting early HIV infection and rapidly initiating ART, tested in *Sabes,* by estimating the number and proportion of new infections averted over 20 years, as well as the reduction in HIV incidence among MSM and TW due to the intervention. Our analysis may be of public-health significance not only for Peru but also for other settings where *Sabes*-like interventions are considered.

2. Methods {#sec2}
==========

2.1. Model {#sec2.1}
----------

We developed a compartmental mathematical model (see model diagram, [Fig. 1](#fig1){ref-type="fig"}) to simulate the HIV epidemic among MSM and TW in Peru and assess the benefits from the intervention tested in *Sabes*. The individuals in the simulated population are divided into groups by risk using number of sexual partners as a surrogate (high: ≥5 male and/or TW partners in 3 months, low: \<5 male and/or TW partners in 3 months) but also by age (15--24 years, 25--34 years, and 35--49 years) and sexual role during anal intercourse (insertive, receptive and versatile). The population is additionally stratified by HIV infection status and CD4 cells per mm^3^ (acute HIV infection, CD4 \> 500, CD4 350-500, CD4 200-350, and CD4\<200). Infected individuals are assigned to compartments by treatment status (not diagnosed, diagnosed but not on ART, not virally suppressed on ART, and virally suppressed on ART). Complete model description including model equations is provided in the Supplement.Fig. 1**Flow diagram of the model.** Simulated population is stratified in compartments by HIV infection status and progression towards AIDS during five disease phases. Infected individuals are additionally stratified by treatment status as undiagnosed (compartments I), diagnosed who are not in care (compartments D), diagnosed in care not in treatment (compartment E), diagnosed on ART but virally unsuppressed (compartment U) and diagnosed on ART virally suppressed (compartment T). MSM who become sexually active join the susceptible compartment (S) at constant rate. Population is additionally stratified by age, HIV risk and sexual positioning which is not shown in the diagram. A complete description of the model including the expressions for the forces of infections (λ) is presented in the Supplement.Fig. 1

2.2. Model parameterization {#sec2.2}
---------------------------

The model is parameterized with epidemiological data representative of the HIV epidemic among MSM and TW in Peru. Demographic and sexual behavior characteristics including average number of partners per year, frequency of sex acts, proportion of acts protected by condoms, and lifetime duration of sexual activity are estimated from published data (see [Table 1](#tbl1){ref-type="table"}). The mixing between age and risk subgroups is informed from data collected in *Sabes*. The number of partners used in the analysis (see [Table S1](#appsec1){ref-type="sec"} in the Supplement) for the subgroups by age and risk are the average annual numbers based on reported partnerships over 3-month period by Sabes participants in each subgroup. We balance the overall number of partnerships between population subgroups by continually updating the fraction of partners someone with a given risk, role and age has from the other subgroups. Complete list of fixed parameter values used in the analysis is presented in the Supplement, [Table S1](#appsec1){ref-type="sec"}.Table 1Key behavioral, epidemic and intervention parameters used in the analysis.Table 1DescriptionValue (range)RefMSM population size at the start of the simulation in 2004400,000[@bib12]HIV acquisition risk per sexual act with infected partner in asymptomatic HIV stage (CD4 \>200)0.1%--0.2%([@bib1]; [@bib26])Relative infectiousness of acutely infected MSM compared to MSM with CD4\>20026[@bib23]Multiplier of HIV acquisition risk per sexual act with infected partner with ^12^CD4\<2003calculated ([@bib23])Average number of sexual acts per year in main partnerships40--60assumedAverage number of sexual acts per year in short-term partnerships2--5assumedAverage number of sexual partners per year of low risk MSM1.3--1.7SABES dataAverage number of sexual partners per year of high risk MSM51--58SABES dataProportion of sex acts protected by condom50%([@bib32]; [@bib41])Efficacy of condom in preventing HIV transmission per anal act70%--90%[@bib44]Reduction of HIV infectiousness of virally-suppressed MSM on ART100%([@bib2]; [@bib39])Reduction of HIV infectiousness of virally-unsuppressed MSM on ART30%--70%assumedAverage time to initiate ART for newly diagnosed MSM who meet eligibility criteria at the time6--10 monthsestimated to fit cascadeAnnual ART drop rate6%--8%[@bib38]

2.3. Model calibration {#sec2.3}
----------------------

In order to calibrate the model, we fit its outputs to the HIV prevalence and the treatment cascade among MSM and TW in Peru ([Table 2](#tbl2){ref-type="table"}) using a calibration procedure described in the Supplement. Monte Carlo filtering is used to select 1000 parameter sets closely matching the 2011--2012 epidemiological data ([@bib3]; [@bib12]) and used in the analysis (see [Fig. 2](#fig2){ref-type="fig"}A--D). Complete list of parameter ranges used in the calibration procedure is presented in the Supplement, [Table S2](#appsec1){ref-type="sec"}. Posterior distributions of the model parameters resulting from the calibration procedure are shown in [Fig. S1](#appsec1){ref-type="sec"}.Table 2Calibration targets used in the analysis.Table 2ParameterDescriptionRangeReferenceHIV prevalencePercent of MSM population who have HIV in 201113.4% −14.3%[@bib3]HIV diagnosedPercent of infected MSM who are diagnosed with HIV in 201216%--33.6%[@bib12]Engaged in carePercent of diagnosed MSM who are engaged in care in 201253.2%--75.5%[@bib12]On ARTPercent of infected MSM engaged in care who are on ART in 201282.8%--90.7%[@bib12]On ART, virally suppressedPercent of infected MSM on ART, virally suppressed in 201287.3%--89.5%[@bib12]Fig. 2**Model Calibration** Main reference scenario dynamics of A) HIV prevalence among MSM in Peru; B) fraction of HIV + MSM who are diagnosed; C) ART coverage among MSM in care; D) percentage of all MSM on ART who are virally suppressed; E) care cascade from 2004 to 2038 presented as fractions of all infected being diagnosed, engaged in care, on ART and virally suppressed; F) HIV incidence among high- and low-risk MSM from 2004 to 2038. Initially, ART is offered to infected individuals with CD4 \< 200 cells per mm^3^ only, later expanded to individuals with CD4 \< 350 at the end of 2011 and to individuals with CD4 \< 500 at the end of 2014. Universal access to ART is introduced in 2018.1000 epidemic simulations are selected to meet the HIV prevalence and care cascade targets (red bars in panels A--D) in 2012.Fig. 2

2.4. Assumptions {#sec2.4}
----------------

We have modeled the acute infection period as the three months after HIV acquisition, which includes both the seronegative interval (Fiebig stages 1 and 2) and the early post-seroconversion period. In the absence of intervention, we assume that the AHI is not detected due to its short duration and the standard use of serologic assays; therefore, ART is not initiated during AHI. We assume those who are virally suppressed are not infectious, and MSM who are not virally suppressed, but on ART, are 30--70% less infectious relative to those who are not on ART. Individuals on ART may interrupt treatment and reinitiate. Universal access to ART by all HIV-infected MSM after 2018 is assumed in the main reference scenario with no changes in the calibrated rates of HIV diagnosis and ART initiation rates for each CD4 group maintained unchanged until 2038. Alternatively, we explored a more optimistic reference scenario, assuming elevated rates of HIV diagnosis after 2018 (up to three times the HIV diagnosis rate prior to 2018) leading to an improved care cascade, to study the importance of the background epidemic conditions for the impact of the *Sabes* intervention.

Susceptible MSM who become sexually active join the community at a constant rate, corresponding to the estimated population growth among the MSM population in Peru ([@bib25]). The rates at which individuals acquire HIV infection depend on the annual number of partners per susceptible person, the number of sex acts per partnership, the fraction of sex acts protected by condoms, and the HIV acquisition risk per receptive and insertive anal intercourse with an HIV infected partner obtained from meta-analyses of the published data ([@bib1]; [@bib26]).

2.5. Simulations {#sec2.5}
----------------

The model is used to simulate HIV epidemics without intervention to provide a reference scenario for the evaluation of the impact of the intervention. We evaluated the effectiveness of the intervention over the 2018--2038 period by comparing the intervention to the reference scenario. In the main reference scenario (starting in 2004), we assume that ART is initially offered to infected individuals with CD4 \< 200 cells per mm^3^ only, with eligibility expanded to individuals with CD4 \< 350 at the end of 2011 and to individuals with CD4 \< 500 at the end of 2014. We assumed that ART was offered to all HIV-infected persons, regardless of CD4 count, in 2018.

The *Sabes* intervention included several components to promote early diagnosis and treatment. These included the following: 1) monthly HIV testing, 2) use of HIV RNA tests as well as serologic assays, 3) use of peer health navigators to facilitate rapid linkage to care and 4) immediate ART initiation regardless of CD4 count. In the intervention scenarios, we simulated "Sabes like" intervention by assuming that different proportions of acutely infected MSM were diagnosed, linked to care and initiated ART within 1 month of diagnosis. We also model interventions targeting only acutely infected MSM from the high-risk group, which constitutes an estimated 56% of the total MSM population in Peru.

2.6. Intervention impact {#sec2.6}
------------------------

The impact of HIV programs are often evaluated over 20--30 years of intervention in published modeling analyses and effectiveness studies. Here we project the effectiveness of "Sabes like" intervention for each scenario over 20 years of intervention using the following effectiveness metrics: i) cumulative fraction of HIV infections prevented; ii) reduction in HIV incidence and iii) reduction in HIV prevalence due to the enhanced ART program. All metrics are compared across intervention coverage levels for 1000 simulations using the preselected sets of epidemic parameters identified in the calibration procedure.

2.7. Sensitivity analysis {#sec2.7}
-------------------------

The influence of key parameters on the effectiveness metrics (cumulative fraction of HIV infections prevented and reduction in HIV incidence) is studied in a multivariate sensitivity analysis. Partial rank correlation coefficients (PRCC) are calculated for each parameter-outcome pair as robust sensitivity measure for nonlinear but monotonic relationship between input and outcomes ([@bib4]; [@bib30]). The analysis is based on 1000 simulations identified in the calibration procedure. Only one parameter from highly correlated pairs is included in the analysis.

3. Results {#sec3}
==========

In the main reference scenario, our analysis estimates that the proportion of HIV infected MSM and TW who are diagnosed will rise to 28% by 2018, with the proportion of virally suppressed reaching 19.3% ([Fig. 2](#fig2){ref-type="fig"}E). The HIV incidence in 2018 is expected to be 1.6 per 100 person-years (pyrs) among all MSM in Peru ([Fig. 2](#fig2){ref-type="fig"}F), with substantially higher incidence in high-risk MSM (2.3/100 pyrs) compared to low-risk MSM (0.7/100 pyrs). Maintaining constant rates of ART initiation, 131,000 new HIV infections are expected over the 20-year period 2018--2038 in the absence of the *Sabes* intervention, with approximately 50,000 of them transmitted by infected MSM in early (acute) phase. Our model projects that the HIV incidence will remain practically unchanged and that approximately 80,000 MSM will be living with HIV in Peru in 2038, a 24.6% increase over 2018, with a small improvement in the care cascade expected (26.2% of the infected MSM being virally suppressed). In comparison, the more optimistic reference scenario, which triples the HIV diagnosis rate after 2018, will result in a significantly improved care cascade, with the diagnosed fraction of infected MSM reaching 55% and the virally suppressed fraction reaching 42% in 2038 (see Supplement, [Fig. S1](#appsec1){ref-type="sec"}). As a result, overall HIV incidence is projected to decrease to 1/100 pyrs and the number of new infections over 20 years to drop by approximately 20,000 compared to the main reference scenario.

Under the assumptions of the main reference scenario, we modeled the addition of the *Sabes* intervention and assumed that 10% of the acutely infected MSM were diagnosed, linked to HIV care and initiated ART within 1 month of diagnosis. This intervention resulted in a projected reduction in the number of new HIV infections of 13.3% \[UI: 11.9%--14.3%\] over 20 years while reducing the HIV prevalence by 12.6% and HIV incidence by more than 24% by 2038 ([Fig. 3](#fig3){ref-type="fig"}). Reaching 25% and 50% of all acutely infected MSM in Peru regardless of their risk level is expected to reduce HIV incidence in 2038 by more than 45% and 65% and prevent 27% and 41% of the new infections between 2018 and 2038, respectively. At this scale, the intervention is expected to alter the care cascade substantially. HIV diagnosis and ART initiation of 50% of the acutely infected MSM beginning in 2018 will increase the diagnosed proportion of HIV + MSM in 2038 to 68% and the overall prevalence of viral suppression to 59% compared to 26% in absence of intervention (Supplement, [Fig. S3A](#appsec1){ref-type="sec"}).Fig. 3**Projected impact of the *Sabes* intervention in the main analysis.** A) Effectiveness in terms of cumulative fraction of infections prevented; B) Effectiveness in terms of reduction in HIV incidence; C) Effectiveness in terms of reduction in HIV prevalence; D) Estimated contribution of the acute infections to the HIV epidemic. The impact indicators are calculated using the reference scenario without intervention as a baseline. Box plots reflect estimated variation (interquartile range and 90% uncertainty interval \[UI\]) over 1000 epidemic simulations selected in the calibration procedure while the solid lines represent the median effectiveness estimates.Fig. 3

Our analysis suggests that an intervention targeting high-risk MSM who constitute 56% of the total MSM population (see Supplement, [Fig. S4](#appsec1){ref-type="sec"}). Will be highly efficient. Reaching 50% of the high-risk MSM during acute HIV infection is projected to have impact comparable to non-targeted intervention at potentially lower cost. It is expected to reduce HIV incidence in 2038 by 60% and prevent 36% of the new infections between 2018 and 2038.

Our model projects that between 35% and 40% of the annual number of HIV infections among MSM in Peru result from contacts with acutely infected partners ([Fig. 3](#fig3){ref-type="fig"}D). This proportion is not affected significantly by the modeled intervention. It is reduced by less than five percent over 20 years when 50% of the acutely infected are diagnosed and initiate ART within 1 month of diagnoses.

The alternative optimistic reference scenario, which assumed elevated rates of HIV diagnosis after 2018, is expected to influence the course of the HIV epidemic (see Supplement, [Figs. S1E and F](#appsec1){ref-type="sec"}). However, the *Sabes* intervention is projected to have a comparable impact under both scenarios. Analysis of the correlation between the pre-intervention conditions and intervention effectiveness suggests that better viral suppression at the start of the intervention will result in larger reduction in HIV incidence after 20 years (Supplement, [Fig. S3B](#appsec1){ref-type="sec"}).

The partial rank correlation coefficients (PRCC) between parameters varied in the analysis and the effectiveness metrics are presented in the Supplement, [Fig. S5](#appsec1){ref-type="sec"}. They suggest that assumptions about the rate of achieving viral suppression and ART efficacy for virally unsuppressed MSM are most important for both, infections prevented and reduction in HIV incidence due to the intervention. Not surprisingly, increased rate of sexual activity which results in elevated HIV risk is associated with smaller fraction of prevented infections.

4. Discussion {#sec4}
=============

Published reports suggest that the HIV epidemic in Peru is concentrated in MSM and TW with high HIV prevalence, comparable to the prevalence observed in USA or among some heterosexual populations of sub-Saharan Africa. Ongoing incidence among MSM and TW is estimated to contribute to more than 95% of the new infections in Peru in 2016 ([@bib53]). Additional evidence suggests that current HIV testing and treatment programs among MSM and TW in Peru are not effective in reducing HIV transmission due to suboptimal levels of linkage to care and viral suppression among HIV-infected MSM and TW ([@bib12]).

In this study we assessed the effectiveness of a novel HIV prevention strategy, tested in the *Sabes* study, based on seeking, testing, treating and retaining HIV-infected MSM with recent infections ([@bib28]). Our modeling analysis demonstrated that early detection of HIV infections among MSM and TW in Peru is desirable as it would increase the effectiveness of the HIV prevention program, especially if a high proportion of acutely infected MSM are diagnosed and rapidly initiated on ART. If the intervention could identify half of the acutely infected MSM and TW and initiate ART rapidly, we could expect a 3-fold decrease in HIV incidence and more than a 40% reduction in the number of HIV infections over 20 years. Moreover, we project that interventions targeting high-risk MSM with large number of sex partners will be more efficient due to disproportionate number of infections attributed to transmission from this group. An intervention reaching 50% of the high-risk MSM and TW, which results in 28% overall coverage, is expected to have an impact comparable to a non-targeted intervention with 50% coverage.

In addition to the analysis of the impact of enhanced testing and treatment our model allowed us to estimate the population attributable fraction (PAF) associated with acute HIV infections. PAF measures the contribution of a risk factor to a disease. ([@bib55]) The PAF of acute HIV is the proportional reduction in annual HIV transmissions that would occur if exposure to HIV from acutely infected partners was completely eliminated. Mathematical models have a long history of estimating the PAF associated with acute HIV, using estimates which vary considerably between studies ([@bib31]). Our analysis suggests that approximately a third of the annual new infections among MSM and TW in Peru could be attributed to transmission during acute HIV, which was higher than modeling estimates representative for MSM communities in Australia (19%) ([@bib52]) and high risk behavior MSM in Amsterdam (25%) ([@bib56]) but lower than modeling estimates in the UK (48%) ([@bib35]) and Detroit, Michigan, US (45%) ([@bib51]), where all transmissions occurring during the first year after infection were included. Our acute PAF estimate is also high compared to another modeling analysis for MSM in Lima, Peru ([@bib21]) and the difference can be attributed to shorter and less infectious acute period assumed in the prior study.

What are the key drivers of intervention impact? A substantial part of the intervention effectiveness could be explained by the rapid ART initiation among acutely infected MSM and TW, which eliminates the HIV transmission mostly after the acute phase is over and leads to significant improvement of the overall HIV care cascade over 20 years. Additional benefits from improved life expectancy and quality are not considered here but should be important for cost-benefit analyses preceding implementation of such programs. Although targeting acutely infected MSM, the simulated intervention resulted in relatively small decrease in the acute PAF over time. Assuming that 50% of the acutely infected MSM and TW are identified and accounting for the 1-month delay in their ART initiation, suggests that less than 20% of the infections attributed to acutely infected MSM and TW, would be prevented which is clearly demonstrated by the insignificant drop in PAF over time. As a result, acute PAF reduction has a little contribution to the intervention impact even in the most aggressive intervention scenarios.

A key question is the feasibility of the intervention scenarios simulated in the analysis assuming that up to 50% of MSM with acute HIV infection will be consistently diagnosed and rapidly initiated on ART over prolonged periods of time. Of the 2685 uninfected MSM and TW screened in Sabes, 78.5% agreed to enroll and 62% of those still returning to retest after 12 months ([@bib28]). The majority of the infections identified in the study (79%) were categorized as acquired within 3 months of the time of infection. These results suggest that 50% is a reasonable upper bound for the potential coverage of "Sabes like" intervention. The additional 20% drop in retention during the second year of follow up in Sabes indicated that 25%--30% coverage may be a more realistic target for a sustainable intervention over extended time periods.

This modeling study has some limitations. First, our calibration targets for the HIV care cascade among MSM in Peru were informed by data which was predominately obtained from the capital city, Lima, due to limited data on other regions in Peru. However, scenarios exploring alternative care cascades showed insignificant differences in effectiveness estimates. Second, the sexual mixing matrix between different age and risk subgroups were based on data from *Sabes* study participants, which may not be representative for the entire MSM population. Alternative scenarios assuming proportional mixing demonstrated no influence on the reported results. Third, pre-exposure prophylaxis (PrEP) was not included in the model given that it is not currently included in the prevention and treatment guidelines provided by the Peruvian Ministry of Health, and to date, the proportion of people accessing PrEP has been negligible. Fourth, we were not able to separate MSM and TW based on the lack of power to identify differences between these populations in *Sabes*. Finally, our analysis does not provide a sense of efficiency of the intervention, which may be important for benefits to be considered in the context of the effort and resources needed for their realization. Such analysis will require more detailed data on the number of tests needed to achieve the targeted intervention coverage as well as the cost to keep newly diagnosed MSM and TW on treatment. It is planned as a future research direction of our team. Questions about the asymptotic behavior of the model as dynamical system and particularly about existence and stability of equilibria may be theoretically interesting but remained beyond the scope of this paper. These questions may be studied by existing methodologies ([@bib22]) but obtaining practical results may be hindered by the extreme complexity of the model.

In the *Sabes* study we demonstrated that early HIV detection among MSM in Peru is feasible; herein we have outlined its importance for the success of future HIV prevention programs. Early HIV detection is expected to increase ART coverage substantially and therefore increase the prevalence of viral suppression among HIV-infected MSM. Further analyses which optimize treatment-as-prevention strategies will be warranted with the expected expansion of available HIV prevention tools, including daily and long-acting PrEP, and preventive HIV vaccines.
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==============================
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